Search tips
Search criteria 


Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
Infect Immun. 1986 August; 53(2): 324–330.
PMCID: PMC260878

Arthropathic group A streptococcal cell walls require specific antibody for activation of human complement by both the classical and alternative pathways.


The induction of acute arthritis in rats by a single intraperitoneal injection of group A streptococcal cell wall is associated with the activation of complement. We have therefore investigated the interaction of arthropathic peptidoglycan-polysaccharide complex of streptococcal cell walls and human complement. The incubation of cell wall in normal human serum results in the formation of complexes of cell wall and the C3 and C4 components of complement. Using agammaglobulinemic serum, we have further shown that the activation of complement and formation of complement-cell wall complexes absolutely requires the presence of a small quantity of specific antibody. This antibody is present in normal human immunoglobulin G and is effective as the Fab fragment (alternative pathway). Although antibodies specific for three cell wall epitopes were capable of inducing complement-cell wall complex formation by the classical complement pathway, only anti-A polysaccharide antibody (N-acetyl-D-glucosamine epitope) was effective by the alternative complement pathway. A complement consumption assay showed that anti-cell wall antibody was required not only for complement-cell wall complex formation, but also for activation of complement by streptococcal cell wall in human serum. These studies suggest that a minimal level of anti-cell wall antibody may be required for the induction of arthritis in rats by streptococcal cell wall.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bjornson AB, Bjornson HS. Participation of immunoglobulin and the alternative complement pathway in opsonization of Bacteroides fragilis and Bacteroides thetaiotaomicron. J Infect Dis. 1978 Sep;138(3):351–358. [PubMed]
  • Coligan JE, Kindt TJ, Krause RM. Structure of the streptococcal groups A, A-variant and C carbohydrates. Immunochemistry. 1978 Nov;15(10-11):755–760. [PubMed]
  • Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang CH. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med. 1977 Dec 1;146(6):1585–1602. [PMC free article] [PubMed]
  • Van Dijk H, Rademaker PM, Willers JM. Determination of alternative pathway of complement activity in mouse serum using rabbit erythrocytes. J Immunol Methods. 1980;36(1):29–39. [PubMed]
  • Edwards MS, Nicholson-Weller A, Baker CJ, Kasper DL. The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med. 1980 May 1;151(5):1275–1287. [PMC free article] [PubMed]
  • Edwards MS, Kasper DL, Jennings HJ, Baker CJ, Nicholson-Weller A. Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol. 1982 Mar;128(3):1278–1283. [PubMed]
  • Eisenberg R, Fox A, Greenblatt JJ, Anderle SK, Cromartie WJ, Schwab JH. Measurement of bacterial cell wall in tissues by solid-phase radioimmunoassay: correlation of distribution and persistence with experimental arthritis in rats. Infect Immun. 1982 Oct;38(1):127–135. [PMC free article] [PubMed]
  • Fearon DT, Austen KF. Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection. N Engl J Med. 1980 Jul 31;303(5):259–263. [PubMed]
  • Fox A, Brown RR, Anderle SK, Chetty C, Cromartie WJ, Gooder H, Schwab JH. Arthropathic properties related to the molecular weight of peptidoglycan-polysaccharide polymers of streptococcal cell walls. Infect Immun. 1982 Mar;35(3):1003–1010. [PMC free article] [PubMed]
  • Greenblatt J, Boackle RJ, Schwab JH. Activation of the alternate complement pathway by peptidoglycan from streptococcal cell wall. Infect Immun. 1978 Jan;19(1):296–303. [PMC free article] [PubMed]
  • Greenblatt JJ, Hunter N, Schwab JH. Antibody response to streptococcal cell wall antigens associated with experimental arthritis in rats. Clin Exp Immunol. 1980 Dec;42(3):450–457. [PubMed]
  • Hill AW, Shears AL, Hibbitt KG. The requirement of specific antibody for the killing of E. coli by the alternate complement pathway in bovine serum. Immunology. 1978 Jan;34(1):131–136. [PubMed]
  • KRAUSE RM, MCCARTY M. Studies on the chemical structure of the streptococcal cell wall. I. The identification of a mucopeptide in the cell walls of groups A and A-variant streptococci. J Exp Med. 1961 Jul 1;114:127–140. [PMC free article] [PubMed]
  • Lachmann PJ, Pangburn MK, Oldroyd RG. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med. 1982 Jul 1;156(1):205–216. [PMC free article] [PubMed]
  • Lambris JD, Allen JB, Schwab JH. In vivo changes in complement induced with peptidoglycan-polysaccharide polymers from streptococcal cell walls. Infect Immun. 1982 Jan;35(1):377–380. [PMC free article] [PubMed]
  • Medof ME, Iida K, Mold C, Nussenzweig V. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med. 1982 Dec 1;156(6):1739–1754. [PMC free article] [PubMed]
  • Moore FD, Jr, Austen KF, Fearon DT. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. J Immunol. 1982 Mar;128(3):1302–1306. [PubMed]
  • Moore FD, Jr, Fearon DT, Austen KF. IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b. J Immunol. 1981 May;126(5):1805–1809. [PubMed]
  • Nicholson-Weller A, Daha MR, Austen KF. Different functions for specific guinea pig IgG1 and IgG2 in the lysis of sheep erythrocytes by C4-deficient guinea pig serum. J Immunol. 1981 May;126(5):1800–1804. [PubMed]
  • Pryzwansky KB, MacRae EK, Lambris JD. Capping of complement receptors on human neutrophils induced by group A streptococcal cell walls. J Immunol. 1983 Apr;130(4):1674–1677. [PubMed]
  • Ratnoff WD, Fearon DT, Austen KF. The role of antibody in the activation of the alternative complement pathway. Springer Semin Immunopathol. 1983;6(4):361–371. [PubMed]
  • Reed WP, Albright EL. Serum factors responsible for killing of Shigella. Immunology. 1974 Jan;26(1):205–215. [PubMed]
  • Ross GD, Newman SL, Lambris JD, Devery-Pocius JE, Cain JA, Lachmann PJ. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin. J Exp Med. 1983 Aug 1;158(2):334–352. [PMC free article] [PubMed]
  • Schwab JH, Allen JB, Anderle SK, Dalldorf F, Eisenberg R, Cromartie WJ. Relationship of complement to experimental arthritis induced in rats with streptococcal cell walls. Immunology. 1982 May;46(1):83–88. [PubMed]
  • Tarr PI, Hosea SW, Brown EJ, Schneerson R, Sutton A, Frank MM. The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation. J Immunol. 1982 Apr;128(4):1772–1775. [PubMed]
  • Winkelstein JA, Shin HS, Wood WB., Jr Heat labile opsonins to Pneumococcus. 3. The participation of immunoglobulin and of the alternate pathway of C3 activation. J Immunol. 1972 Jun;108(6):1681–1689. [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)